Skip to Main content Skip to Navigation
Journal articles

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

Abstract : Among 103 patients with multidrug-resistant HIV who initiated raltegravir, etravirine, and darunavir/ritonavir-containing regimen in the ANRS 139 TRIO trial, 100 participated in extended follow-up and continued study treatment until week 96. Among them, 87 (87%) received an optimized background therapy including either nucleoside reverse transcriptase inhibitors or enfuvirtide, they were 78 (78%) at week 96. At week 96, 88% achieved durable virologic response (<50 copies/mL). CD4 response was maintained (median change of +150 cells/mm(3)). No major toxicity was reported. This triple drug combination showed sustained efficacy and thus should be strongly considered for patients with multiclass-resistant virus.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-00875207
Contributor : Morgane Le Corre <>
Submitted on : Monday, October 21, 2013 - 2:13:16 PM
Last modification on : Thursday, January 14, 2021 - 11:23:52 AM

Identifiers

Citation

Catherine Fagard, Céline Colin, Charlotte Charpentier, Agathe Rami, Christine Jacomet, et al.. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.. Journal of Acquired Immune Deficiency Syndromes, Lippincott, Williams & Wilkins, 2012, 59 (5), pp.489-93. ⟨10.1097/QAI.0b013e31824bb720⟩. ⟨hal-00875207⟩

Share

Metrics

Record views

388